# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
More than 20 million people in the U.S. are living with peripheral artery disease (PAD) yet there have been limited treatment o...
Barclays analyst Matt Miksic maintains Abbott Laboratories (NYSE:ABT) with a Overweight and lowers the price target from $14...
RBC Capital analyst Shagun Singh maintains Abbott Laboratories (NYSE:ABT) with a Outperform and lowers the price target from...
A sentiment of risk aversion looms over the markets during Wednesday’s trading session, triggering midday losses across the boa...
U.S. stocks traded higher this morning, with the Dow Jones index gaining around 200 points on Wednesday. Following the market ...
Abbott Laboratories surpasses expectations with Q1 sales hitting $9.96B, a 10.8% rise driven by robust performance in Medical D...